At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
ARGX-117 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy
In Brief
A Phase 2 clinical trial evaluating ARGX-117 and Placebo for Multifocal Motor Neuropathy. Completed, enrolled 54 participants across 40 sites in 11 countries.
Detailed Summary
This is a phase 2, randomized, double-blinded, placebo-controlled, parallel-group, multicenter trial to evaluate the safety and efficacy of 2 dose regimens of ARGX-117 versus placebo, in participants with MMN previously stabilized with IVIg (intravenous immunoglobulin).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultifocal Motor Neuropathy
CountriesAustria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionJun 2024
TodayJul 2026
First PostedFeb 4, 2022
Enrollment StartMar 31, 2022
Primary CompletionJun 4, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.4 years ago
Interventions
ARGX-117biological
Intravenous administration of ARGX-117
Placeboother
Intravenous administration of placebo